indications for glp-1 Long-term Success of GLP-1s Hinges on More Than Just a Prescription GLP-1 for Diabetes vs GLP-1

Du Toit BMUoFCfAS

Currently, the single-agonist segment holds the maximum share of the GLP-1 market

Wegovy, which is also semaglutide but approved for weight loss

65,66 A network meta-analysis ranked SEMA 0.4 mg first in the resolution of MASH among alternative treatments [surface under the cumulative ranking (SUCRA) = 0.89], higher than liraglutide (SUCRA = 0.84) and resmetirom (SUCRA = 0.44)

Evidence Summary: What the Data Suggest Several phase 2 and observational studies highlight the hepatic benefits of GLP1based treatment: Reduced liver fat: Repeated findings in imaging-based studies support this effect Lower liver enzymes: Consistent reductions in ALT/AST levels Fibrosis improvement: Promising trends in noninvasive markers, though further trials are needed While the strongest evidence comes from patients with obesity or type 2 diabetes, benefits in leaner, metabolically abnormal patients are increasingly documented, suggesting broader utility